Literature DB >> 14576144

In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.

A Liebetrau1, A C Rodloff, J Behra-Miellet, L Dubreuil.   

Abstract

The antimicrobial activities of garenoxacin and eight other antibiotics against 641 anaerobic isolates were evaluated with the NCCLS agar dilution method. Overall, the MICs of garenoxacin for 50 and 90% of the strains tested (in micrograms per milliliter) were as follows: Bacteroides fragilis group, 0.5 and 2; Prevotella spp., 0.25 and 2; Fusobacterium spp., 0.25 and 0.5; Porphyromonas spp., 0.125 and 0.25; Bilophila wadsworthia, 0.5 and 1; Veillonella spp., 0.25 and 0.5; Clostridium spp., 0.25 and 1; Clostridium difficile, 2 and >64; Bifidobacterium spp., 1 and 2; Eggerthella lenta, 0.25 and 1; Propionibacterium spp., 0.5 and 0.5; gram-positive cocci, 0.125 and 0.25.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14576144      PMCID： PMC253765          DOI： 10.1128/AAC.47.11.3667-3671.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

1.  In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.

Authors:  R Schaumann; G Ackermann; B Pless; M C Claros; A C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates.

Authors:  Matteo Bassetti; Louise M Dembry; Patricia A Farrel; Deborah A Callan; Vincent T Andriole
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.

Authors:  M Takahata; J Mitsuyama; Y Yamashiro; M Yonezawa; H Araki; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Survey of the susceptibility patterns of Bacteroides fragilis group strains in France from 1977 to 1992.

Authors:  L Dubreuil; J Breuil; A Dublanchet; A Sedallian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

5.  Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.

Authors:  D R Snydman; N V Jacobus; L A McDermott; S Supran; G J Cuchural; S Finegold; L Harrell; D W Hecht; P Iannini; S Jenkins; C Pierson; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

7.  [Susceptibility of strict anaerobic bacteria to antibiotics in France: a multicenter study].

Authors:  G Grollier; F Mory; C Quentin; F Girard-Pipau; S Tigaud; A Sedallian; L Dubreuil
Journal:  Pathol Biol (Paris)       Date:  1994-05

8.  Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.

Authors:  K E Aldridge; D Ashcraft; K Cambre; C L Pierson; S G Jenkins; J E Rosenblatt
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

9.  Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa.

Authors:  M M Lubbe; P L Botha; L J Chalkley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-01       Impact factor: 3.267

10.  Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development.

Authors:  A M Fix; M A Pfaller; D J Biedenbach; M L Beach; R N Jones
Journal:  Int J Antimicrob Agents       Date:  2001-08       Impact factor: 5.283
View more
  11 in total

1.  Elucidation of the Molecular Mechanisms of Action of the Natural Antimicrobial Peptide Subtilosin Against the Bacterial Vaginosis-associated Pathogen Gardnerella vaginalis.

Authors:  Katia Sutyak Noll; Patrick J Sinko; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2011-03       Impact factor: 4.609

2.  Polymicrobial bloodstream infection with Eggerthella lenta and Desulfovibrio desulfuricans.

Authors:  Karin Liderot; Martin Larsson; Stina Boräng; Volkan Ozenci
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

3.  In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.

Authors:  D Molitoris; M-L Väisänen; M Bolaños; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

4.  Clinical and microbiological characteristics of Eggerthella lenta bacteremia.

Authors:  B J Gardiner; A Y Tai; D Kotsanas; M J Francis; S A Roberts; S A Ballard; R K Junckerstorff; T M Korman
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

Review 5.  The aetiology of bacterial vaginosis.

Authors:  Y Turovskiy; K Sutyak Noll; M L Chikindas
Journal:  J Appl Microbiol       Date:  2011-03-14       Impact factor: 3.772

6.  The natural antimicrobial peptide subtilosin acts synergistically with glycerol monolaurate, lauric arginate, and ε-poly-L-lysine against bacterial vaginosis-associated pathogens but not human lactobacilli.

Authors:  Katia Sutyak Noll; Mark N Prichard; Arkady Khaykin; Patrick J Sinko; Michael L Chikindas
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

7.  Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota.

Authors:  Federica Cruciani; Patrizia Brigidi; Fiorella Calanni; Vittoria Lauro; Raffaella Tacchi; Gilbert Donders; Klaus Peters; Secondo Guaschino; Beatrice Vitali
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

8.  The complex vaginal flora of West African women with bacterial vaginosis.

Authors:  Jacques Pépin; Sylvie Deslandes; Geneviève Giroux; François Sobéla; Nzambi Khonde; Soumaila Diakité; Sophie Demeule; Annie-Claude Labbé; Nathalie Carrier; Eric Frost
Journal:  PLoS One       Date:  2011-09-20       Impact factor: 3.240

9.  Multiple Pyogenic Liver Abscesses Caused by Eggerthella lenta Treated with Ertapenem: A Case Report.

Authors:  Richard M Elias; Shiao Yen Khoo; Jakrapun Pupaibool; Ju-Hsien Nienaber; Nathan W Cummins
Journal:  Case Rep Med       Date:  2012-03-05

10.  Spermicidal activity of the safe natural antimicrobial peptide subtilosin.

Authors:  Katia E Sutyak; Robert A Anderson; Sara E Dover; Kenneth A Feathergill; Alla A Aroutcheva; Sebastian Faro; Michael L Chikindas
Journal:  Infect Dis Obstet Gynecol       Date:  2008-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.